Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

X
Trial Profile

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPI-62 (Primary)
  • Indications Adrenal gland disorders; Cushing syndrome
  • Focus Therapeutic Use
  • Acronyms ACSPIRE
  • Sponsors Sparrow Pharmaceuticals
  • Most Recent Events

    • 16 May 2024 Planned number of patients changed from 150 to 30.
    • 16 May 2024 Status changed from recruiting to active, no longer recruiting.
    • 24 Oct 2023 According to a Sparrow Pharmaceuticals media release, the first patient has been dosed in this trial. The trial is enrolling 30 participants in the United States, soon to be joined by sites in Romania, France, and the United Kingdom. This trial will complement ongoing Phase 2 RESCUE study.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top